{
  "$schema": "folio-library-document/v1",
  "id": "10665-42458",
  "title": "Herpes simplex virus type 2 : programmatic and research priorities in developing countries : report of a WHO/UNAIDS/LSHTM workshop, London, 14-16 February 2001",
  "variant": "pdf",
  "pages": 52,
  "tocSource": "inferred",
  "tocMethod": "contents",
  "toc": [
    {
      "level": 1,
      "title": "ABBREVIATIONS",
      "number": null,
      "page": 5,
      "pageLabel": "iv",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-000-abbreviations"
    },
    {
      "level": 1,
      "title": "EXECUTIVE SUMMARY",
      "number": null,
      "page": 6,
      "pageLabel": "v",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-001-executive-summary"
    },
    {
      "level": 1,
      "title": "INTRODUCTION",
      "number": "1",
      "page": 8,
      "pageLabel": "1",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-002-1-introduction"
    },
    {
      "level": 1,
      "title": "OBJECTIVES",
      "number": "2",
      "page": 9,
      "pageLabel": "2",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-003-2-objectives"
    },
    {
      "level": 1,
      "title": "PARTICIPANTS AND METHODOLOGY",
      "number": "3",
      "page": 10,
      "pageLabel": "3",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-004-3-participants-and-methodology"
    },
    {
      "level": 1,
      "title": "INTERACTION BETWEEN HSV2 AND HIV",
      "number": "5",
      "page": 17,
      "pageLabel": "10",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-006-5-interaction-between-hsv2-and-hiv"
    },
    {
      "level": 2,
      "title": "Biological and clinical research",
      "number": "5.1",
      "page": 17,
      "pageLabel": "10",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-005-51-biological-and-clinical-research"
    },
    {
      "level": 2,
      "title": "Epidemiological research",
      "number": "5.2",
      "page": 18,
      "pageLabel": "11",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-007-52-epidemiological-research"
    },
    {
      "level": 2,
      "title": "Genital ulcer disease in Africa: Epidemiological trends",
      "number": "5.3",
      "page": 20,
      "pageLabel": "13",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-008-53-genital-ulcer-disease-in-africa-epidemiologic"
    },
    {
      "level": 1,
      "title": "HSV2 CONTROL MEASURES FOR DEVELOPING COUNTRIES",
      "number": "6",
      "page": 22,
      "pageLabel": "15",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-009-6-hsv2-control-measures-for-developing-countries"
    },
    {
      "level": 2,
      "title": "Case management of HSV2 in areas of Africa with high HIV prevalence",
      "number": "6.1",
      "page": 22,
      "pageLabel": "15",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-010-61-case-management-of-hsv2-in-areas-of-africa-wi"
    },
    {
      "level": 2,
      "title": "The role of episodic and suppressive therapy in HSV2 and HIV control",
      "number": "6.2",
      "page": 23,
      "pageLabel": "16",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-011-62-the-role-of-episodic-and-suppressive-therapy"
    },
    {
      "level": 2,
      "title": "Vaccine trials",
      "number": "6.3",
      "page": 26,
      "pageLabel": "19",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-012-63-vaccine-trials"
    },
    {
      "level": 2,
      "title": "Other preventive strategies",
      "number": "6.4",
      "page": 30,
      "pageLabel": "23",
      "confidence": 0.8,
      "evidence": [
        "contents",
        "body",
        "number"
      ],
      "source": "inferred",
      "section": "sec-013-64-other-preventive-strategies"
    },
    {
      "level": 1,
      "title": "MATHEMATICAL MODELLING",
      "number": "7",
      "page": 33,
      "pageLabel": "26",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-014-7-mathematical-modelling"
    },
    {
      "level": 1,
      "title": "HSV2 DIAGNOSIS",
      "number": "8",
      "page": 34,
      "pageLabel": "27",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-015-8-hsv2-diagnosis"
    },
    {
      "level": 1,
      "title": "RESEARCH AND CONTROL PROGRAMME PRIORITIES",
      "number": "9",
      "page": 36,
      "pageLabel": "29",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-016-9-research-and-control-programme-priorities"
    },
    {
      "level": 2,
      "title": "Biological studies: HSV2 and its interaction with HIV",
      "number": "9.2",
      "page": 37,
      "pageLabel": "30",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-017-92-biological-studies-hsv2-and-its-interaction-w"
    },
    {
      "level": 2,
      "title": "Episodic and suppressive therapy",
      "number": "9.3",
      "page": 37,
      "pageLabel": "30",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-018-93-episodic-and-suppressive-therapy"
    },
    {
      "level": 2,
      "title": "Vaccination",
      "number": "9.4",
      "page": 39,
      "pageLabel": "32",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-019-94-vaccination"
    },
    {
      "level": 2,
      "title": "Behavioural and microbicide studies",
      "number": "9.5",
      "page": 40,
      "pageLabel": "33",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-020-95-behavioural-and-microbicide-studies"
    },
    {
      "level": 2,
      "title": "Mathematical modelling",
      "number": "9.6",
      "page": 40,
      "pageLabel": "33",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-021-96-mathematical-modelling"
    },
    {
      "level": 2,
      "title": "Diagnosis",
      "number": "9.7",
      "page": 41,
      "pageLabel": "34",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-022-97-diagnosis"
    },
    {
      "level": 1,
      "title": "LIST OF PARTICIPANTS",
      "number": "Annex 1",
      "page": 42,
      "pageLabel": "35",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-023-annex-1-list-of-participants"
    },
    {
      "level": 1,
      "title": "REFERENCES",
      "number": "Annex 2",
      "page": 45,
      "pageLabel": "38",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-024-annex-2-references"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 5,
      "labelStart": null,
      "labelEnd": "iv",
      "words": 565,
      "summary": {
        "text": "Front matter of the 2001 WHO/UNAIDS/LSHTM workshop report on herpes simplex virus type 2 (HSV2) programmatic and research priorities in developing countries, with title pages, document numbers, ISBN and copyright notice, followed by a list of abbreviations. The extracted text also includes stray cover text from an unrelated WHO publication, Guidelines for the management of sexually transmitted infections.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "herpes simplex",
          "heading": false
        },
        {
          "term": "unaids lshtm",
          "heading": false
        },
        {
          "term": "herpes simples",
          "heading": false
        },
        {
          "term": "simplex virus",
          "heading": false
        },
        {
          "term": "hsv",
          "heading": false
        },
        {
          "term": "hiv aids",
          "heading": false
        },
        {
          "term": "research priorities",
          "heading": false
        },
        {
          "term": "lshtm workshop",
          "heading": false
        }
      ],
      "extract": "GUIDELINES WHO/HIV_AIDS/2001.01 WHO/RHR/01.10 Original: English Distr.: General FOR THE MANAGEMENT OF SEXUALLY TRANSMITTED INFECTIONS WORLD HEALTH ORGANIZATION WHO/HIV_AIDS/2001.01 WHO/RHR/01.10 Original: English Distr.: General WORLD HEALTH ORGANIZATION L O N D O N S C H O O L O F H Y G I E N E & T R O P I C A L M E D I C I N E FOR THE M N GEMENT OF SEXUALLY TRANSMITTED INFECTIONS FOR THE MANAGEMENT OF HERPES",
      "extractCut": true,
      "blocks": [
        "library/10665-42458/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-abbreviations",
      "number": null,
      "title": "ABBREVIATIONS",
      "level": 1,
      "pageStart": 5,
      "pageEnd": 6,
      "labelStart": "iv",
      "labelEnd": "v",
      "words": 14,
      "summary": {
        "text": "A running header followed by the heading for the list of abbreviations.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "iv HERPES SIMPLES VIRUS TYPE 2: PROGRAMMATIC AND RESEARCH PRIORITIES IN DEVELOPING COUNTRIES ABBREVIATIONS",
      "extractCut": false
    },
    {
      "id": "sec-001-executive-summary",
      "number": null,
      "title": "EXECUTIVE SUMMARY",
      "level": 1,
      "pageStart": 6,
      "pageEnd": 8,
      "labelStart": "v",
      "labelEnd": "1",
      "words": 593,
      "summary": {
        "text": "Summarises the report, explaining that HSV2 is the main cause of genital ulcer disease, is very common where HIV epidemics are severe, and may facilitate HIV transmission in a two-way interaction. It notes that the workshop reviewed evidence and set priorities across epidemiology, HSV2–HIV interaction, therapy, vaccines and behavioural and microbicide studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "genital ulcer",
          "heading": false
        },
        {
          "term": "genital herpes",
          "heading": false
        },
        {
          "term": "hsv",
          "heading": false
        },
        {
          "term": "herpes simples",
          "heading": false
        },
        {
          "term": "executive summary",
          "heading": true
        },
        {
          "term": "ulcer disease",
          "heading": false
        },
        {
          "term": "research priorities",
          "heading": false
        },
        {
          "term": "developing countries",
          "heading": false
        }
      ],
      "extract": "Herpes simplex virus type 2 (HSV2) infection is the primary cause of genital herpes. It is highly prevalent in human populations in many parts of the world, and is the most common cause of genital ulcer disease worldwide. In developing countries, the major public health importance of HSV2 relates to its potential role in facilitating HIV transmission. HSV2 is highly prevalent in most regions experiencing severe HIV",
      "extractCut": true
    },
    {
      "id": "sec-002-1-introduction",
      "number": "1",
      "title": "INTRODUCTION",
      "level": 1,
      "pageStart": 8,
      "pageEnd": 9,
      "labelStart": "1",
      "labelEnd": "2",
      "words": 358,
      "summary": {
        "text": "Introduces the workshop by setting out the public health importance of HSV2 in developing countries and its suspected role in HIV spread. It explains that experts from developing and industrialized countries were invited to consider control measures.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "genital herpes",
          "heading": false
        },
        {
          "term": "genital ulcer",
          "heading": false
        },
        {
          "term": "hsv",
          "heading": false
        },
        {
          "term": "ulcer disease",
          "heading": false
        },
        {
          "term": "hiv transmission",
          "heading": false
        },
        {
          "term": "developing countries",
          "heading": false
        },
        {
          "term": "virus type",
          "heading": false
        },
        {
          "term": "infectiousness",
          "heading": false
        }
      ],
      "extract": "Herpes simplex virus type 2 (HSV2) infection is the primary cause of genital herpes. It is highly prevalent in human populations in many parts of the world, and is the most common cause of genital ulcer disease worldwide. In developing countries, the major public health importance of HSV2 relates to its potential role in facilitating HIV transmission. HSV2 is highly prevalent in most regions experiencing severe HIV",
      "extractCut": true
    },
    {
      "id": "sec-003-2-objectives",
      "number": "2",
      "title": "OBJECTIVES",
      "level": 1,
      "pageStart": 9,
      "pageEnd": 10,
      "labelStart": "2",
      "labelEnd": "3",
      "words": 75,
      "summary": {
        "text": "States the workshop's objectives: to review knowledge on HSV2 epidemiology, its interaction with HIV, control measures and diagnostics, to identify knowledge gaps, and to set research and programme priorities.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hsv",
          "heading": false
        },
        {
          "term": "objectives",
          "heading": true
        },
        {
          "term": "developing countries",
          "heading": false
        }
      ],
      "extract": "1. To review existing knowledge in the following four areas, with a particular focus on developing countries: ■The epidemiology and natural history of HSV2 ■The interaction between HSV2 and HIV ■HSV2 control measures ■HSV2 diagnostics. 2.To identify important gaps in knowledge in each of these areas requiring further study. 3.To establish priorities for future research and control programmes. 2. OBJECTIVES 2 2.",
      "extractCut": true
    },
    {
      "id": "sec-004-3-participants-and-methodology",
      "number": "3",
      "title": "PARTICIPANTS AND METHODOLOGY",
      "level": 1,
      "pageStart": 10,
      "pageEnd": 17,
      "labelStart": "3",
      "labelEnd": "10",
      "words": 2316,
      "summary": {
        "text": "Describes the 40 participants and the workshop's format of presentations, breakout groups and plenary prioritisation. It then reviews the epidemiology and natural history of HSV2, including rising prevalence worldwide and its role as the leading cause of genital ulcer disease. Table 1 gives seroprevalence figures for general populations in Africa, Latin America and Asia, and the section discusses HSV2 as a marker of sexual behaviour. It ends with recommended studies, including of discordant couples, with attention to counselling and treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hsv shedding",
          "heading": false
        },
        {
          "term": "hsv seroprevalence",
          "heading": false
        },
        {
          "term": "hsv prevalence",
          "heading": false
        },
        {
          "term": "hsv infection",
          "heading": false
        },
        {
          "term": "hsv serology",
          "heading": false
        },
        {
          "term": "hsv transmission",
          "heading": false
        },
        {
          "term": "hsv acquisition",
          "heading": false
        },
        {
          "term": "hsv incidence",
          "heading": false
        }
      ],
      "extract": "Forty participants attended the workshop (Annex 1), and areas of expertise included virology, epidemiology, surveillance, behavioural science, clinical medicine, mathematical modelling and STI programme development and implementation in developing countries. Participants came from Africa (10),Asia (1), Europe (18) and North America (7). In addition, three representatives of UN agencies were present, and one from",
      "extractCut": true
    },
    {
      "id": "sec-005-51-biological-and-clinical-research",
      "number": "5.1",
      "title": "Biological and clinical research",
      "level": 2,
      "pageStart": 17,
      "pageEnd": 17,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 301,
      "summary": {
        "text": "Explains the two-way biological interaction between HIV and HSV2, with HIV increasing HSV2 reactivation, shedding and severity, and HSV2 lesions containing HIV. It notes some evidence that aciclovir may prolong survival in people with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hsv shedding",
          "heading": false
        },
        {
          "term": "hsv reactivation",
          "heading": false
        },
        {
          "term": "hsv lesions",
          "heading": false
        },
        {
          "term": "hiv rna",
          "heading": false
        },
        {
          "term": "hiv seropositive",
          "heading": false
        },
        {
          "term": "plasma hiv",
          "heading": false
        },
        {
          "term": "hiv transmission",
          "heading": false
        },
        {
          "term": "augenbraun",
          "heading": false
        }
      ],
      "extract": "HIV and HSV2 manifest a bi-directional interaction. HSV2 increases the efficiency of HIV acquisition and transmission whereas HIV may increase susceptibility to HSV2 and increase HSV2 shedding, HSV2 recurrence rate and severity of clinical manifestations. EFFECT OF HIV INFECTION ON NATURAL HISTORY OF HSV2 HSV2 reactivation and duration of recurrences are significantly increased in HIV infected individuals",
      "extractCut": true
    },
    {
      "id": "sec-006-5-interaction-between-hsv2-and-hiv",
      "number": "5",
      "title": "INTERACTION BETWEEN HSV2 AND HIV",
      "level": 1,
      "pageStart": 17,
      "pageEnd": 18,
      "labelStart": "10",
      "labelEnd": "11",
      "words": 282,
      "summary": {
        "text": "Continues the review of how HSV2 may increase HIV shedding, noting that aciclovir lowers both viruses in lesions and that data from developing countries are lacking. It lists recommended biological studies, such as whether the effect differs in Africa because of co-infections.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hsv",
          "heading": true
        },
        {
          "term": "hiv shedding",
          "heading": false
        },
        {
          "term": "hiv rna",
          "heading": false
        },
        {
          "term": "genital lesions",
          "heading": false
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "interaction",
          "heading": true
        },
        {
          "term": "subclinical",
          "heading": false
        },
        {
          "term": "developing countries",
          "heading": false
        }
      ],
      "extract": "10 5. INTERACTION BETWEEN HSV2 AND HIV HERPES SIMPLES VIRUS TYPE 2: PROGRAMMATIC AND RESEARCH PRIORITIES IN DEVELOPING COUNTRIES association between genital HIV RNA and HSV2 DNA levels, but some association of quantity of HIV and HSV2 shedding among dually shedding women [Mbopi-Keou et al., 2000]. HIV RNA is often present at high titres in genital lesions (independent of plasma RNA levels), but titres of both HIV1",
      "extractCut": true
    },
    {
      "id": "sec-007-52-epidemiological-research",
      "number": "5.2",
      "title": "Epidemiological research",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 20,
      "labelStart": "11",
      "labelEnd": "13",
      "words": 612,
      "summary": {
        "text": "Summarises epidemiological evidence that HSV2 raises the risk of acquiring HIV, from a meta-analysis showing about a two-fold risk in men and weaker findings in women. It discusses why cross-sectional studies show stronger associations and recommends prospective studies and estimates of population attributable fractions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hsv",
          "heading": false
        },
        {
          "term": "hiv-discordant couples",
          "heading": false
        },
        {
          "term": "hiv acquisition",
          "heading": false
        },
        {
          "term": "herpes simples",
          "heading": false
        },
        {
          "term": "incident hiv",
          "heading": false
        },
        {
          "term": "prospective studies",
          "heading": false
        },
        {
          "term": "case-control studies",
          "heading": false
        },
        {
          "term": "hiv transmission",
          "heading": false
        }
      ],
      "extract": "EFFECT OF HSV2 ON HIV ACQUISITION Evidence for the effect of HSV2 on acquisition of HIV comes from epidemiological studies, and results of a meta-analysis of the relationships between the two infections were presented [Wald and Link, unpublished]. Nine prospective studies (four cohort 5. INTERACTION BETWEEN HSV2 AND HIV 11 HERPES SIMPLES VIRUS TYPE 2: PROGRAMMATIC AND RESEARCH PRIORITIES IN DEVELOPING COUNTRIES",
      "extractCut": true
    },
    {
      "id": "sec-008-53-genital-ulcer-disease-in-africa-epidemiologic",
      "number": "5.3",
      "title": "Genital ulcer disease in Africa: Epidemiological trends",
      "level": 2,
      "pageStart": 20,
      "pageEnd": 22,
      "labelStart": "13",
      "labelEnd": "15",
      "words": 493,
      "summary": {
        "text": "Describes changes in the causes of genital ulcer disease in Africa, with Table 2 showing herpes rising and chancroid and syphilis falling at a South African mine clinic from 1986 to 1998. It notes that this undermines syndromic management and recommends monitoring ulcer causes by sex, HIV status and risk group.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "chancroid lgv",
          "heading": false
        },
        {
          "term": "chancroid rpr",
          "heading": false
        },
        {
          "term": "herpes chancroid",
          "heading": false
        },
        {
          "term": "gud aetiology",
          "heading": false
        },
        {
          "term": "genital herpes",
          "heading": false
        },
        {
          "term": "herpes simples",
          "heading": false
        },
        {
          "term": "mine sti",
          "heading": false
        },
        {
          "term": "gold mine",
          "heading": false
        }
      ],
      "extract": "Chancroid, syphilis and genital herpes are all common causes of genital ulcer disease (GUD) in developing countries. However, there is some evidence that there have been changes in the aetiology of GUD in recent years [O’Farrell, 1999], and this may influence the appropriateness of current syndromic management. Table 2 shows data from a gold mine STI clinic in South Africa from 1986 to 1998 [Htun et al., 2001].The",
      "extractCut": true
    },
    {
      "id": "sec-009-6-hsv2-control-measures-for-developing-countries",
      "number": "6",
      "title": "HSV2 CONTROL MEASURES FOR DEVELOPING COUNTRIES",
      "level": 1,
      "pageStart": 22,
      "pageEnd": 22,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-010-61-case-management-of-hsv2-in-areas-of-africa-wi",
      "number": "6.1",
      "title": "Case management of HSV2 in areas of Africa with high HIV prevalence",
      "level": 2,
      "pageStart": 22,
      "pageEnd": 23,
      "labelStart": "15",
      "labelEnd": "16",
      "words": 399,
      "summary": {
        "text": "Explains why clinical diagnosis of genital ulcers is unreliable where HIV is common and why rising herpes cases may increase syndromic treatment failure. It recommends lobbying for affordable aciclovir, evaluating its addition to syndromic algorithms, and strengthening health education.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv prevalence",
          "heading": true
        },
        {
          "term": "hsv",
          "heading": true
        },
        {
          "term": "aciclovir",
          "heading": false
        },
        {
          "term": "herpetic ulcers",
          "heading": false
        },
        {
          "term": "syndromic management",
          "heading": false
        },
        {
          "term": "gud",
          "heading": false
        },
        {
          "term": "clinical presentation",
          "heading": false
        },
        {
          "term": "developing countries",
          "heading": false
        }
      ],
      "extract": "IN AREAS OF AFRICA WITH HIGH HIV PREVALENCE Clinical diagnosis of GUD is unreliable, reflecting similarities between the clinical presentation of different GUDs, the presence of mixed infections and atypical ulceration due to longstanding disease (associated with delay in seeking health care).As mentioned in Section 5, HIV may alter the clinical presentation of HSV2. In areas of high HIV prevalence, herpetic ulcers",
      "extractCut": true
    },
    {
      "id": "sec-011-62-the-role-of-episodic-and-suppressive-therapy",
      "number": "6.2",
      "title": "The role of episodic and suppressive therapy in HSV2 and HIV control",
      "level": 2,
      "pageStart": 23,
      "pageEnd": 26,
      "labelStart": "16",
      "labelEnd": "19",
      "words": 1015,
      "summary": {
        "text": "Compares episodic and suppressive therapy for genital herpes with aciclovir, valaciclovir and famciclovir, summarising their effects on symptoms, shedding and recurrences. It considers how such therapy might reduce HIV transmission or acquisition. It recommends randomised trials in high-risk groups, such as serodiscordant couples and sex workers, with monitoring for drug resistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "episodic therapy",
          "heading": true
        },
        {
          "term": "suppressive therapy",
          "heading": true
        },
        {
          "term": "hsv control",
          "heading": true
        },
        {
          "term": "hsv shedding",
          "heading": false
        },
        {
          "term": "suppressive aciclovir",
          "heading": false
        },
        {
          "term": "hsv isolates",
          "heading": false
        },
        {
          "term": "hsv antiviral",
          "heading": false
        },
        {
          "term": "hsv transmission",
          "heading": false
        }
      ],
      "extract": "IN HSV2 AND HIV CONTROL Two main treatment strategies are possible for herpes: episodic and suppressive treatment. ■Episodic therapy: ➔Treatment of primary genital herpes ➔Treatment of recurrent genital herpes ■Suppressive therapy: ➔To prevent recurrences. Aciclovir is an antiviral drug, which has been the standard treatment for genital herpes for the past decade in developed countries.Two new therapeutic agents",
      "extractCut": true
    },
    {
      "id": "sec-012-63-vaccine-trials",
      "number": "6.3",
      "title": "Vaccine trials",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 30,
      "labelStart": "19",
      "labelEnd": "23",
      "words": 1138,
      "summary": {
        "text": "Discusses prophylactic and therapeutic HSV2 vaccines, the immune responses they should induce and the results of recent candidate vaccine trials. It considers how vaccine trials could be designed in developing countries, with HSV2 disease as the main endpoint and HIV infection as a secondary one.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hsv vaccine",
          "heading": false
        },
        {
          "term": "genital hsv",
          "heading": false
        },
        {
          "term": "subunit hsv",
          "heading": false
        },
        {
          "term": "hsv infection",
          "heading": false
        },
        {
          "term": "hsv infected",
          "heading": false
        },
        {
          "term": "disc vaccine",
          "heading": false
        },
        {
          "term": "against hsv",
          "heading": false
        },
        {
          "term": "hsv disease",
          "heading": false
        }
      ],
      "extract": "Given the high prevalence of HSV2 infection in many countries, and the fact that most infections are subclinical, the development of an effective HSV2 vaccine would provide a powerful control tool. HSV2 vaccines can be divided into two main categories according to whether they target infected or uninfected individuals. Prophylactic vaccines: aim at protecting against HSV infection or disease in the uninfected",
      "extractCut": true
    },
    {
      "id": "sec-013-64-other-preventive-strategies",
      "number": "6.4",
      "title": "Other preventive strategies",
      "level": 2,
      "pageStart": 30,
      "pageEnd": 33,
      "labelStart": "23",
      "labelEnd": "26",
      "words": 753,
      "summary": {
        "text": "Reviews other HSV2 prevention strategies where vaccines and therapy are not feasible, including behavioural interventions, condoms and female-controlled methods such as microbicides. It also covers counselling and states that widespread HSV2 screening was not recommended at that stage.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hsv seropositive",
          "heading": false
        },
        {
          "term": "against hsv",
          "heading": false
        },
        {
          "term": "hsv control",
          "heading": false
        },
        {
          "term": "hsv infection",
          "heading": false
        },
        {
          "term": "hsv screening",
          "heading": false
        },
        {
          "term": "herpes simples",
          "heading": false
        },
        {
          "term": "herpes lesions",
          "heading": false
        },
        {
          "term": "genital herpes",
          "heading": false
        }
      ],
      "extract": "In the absence of a vaccine or feasible therapeutic strategy in many developing countries, other preventive strategies are needed for HSV2 (and HIV) control. Discussions focused on female-controlled methods and behavioural interventions. REDUCING EXPOSURE TO THE VIRUS As with other sexually transmitted infections, behavioural interventions are needed.The format of these interventions will depend on current HSV2",
      "extractCut": true
    },
    {
      "id": "sec-014-7-mathematical-modelling",
      "number": "7",
      "title": "MATHEMATICAL MODELLING",
      "level": 1,
      "pageStart": 33,
      "pageEnd": 34,
      "labelStart": "26",
      "labelEnd": "27",
      "words": 243,
      "summary": {
        "text": "Describes how mathematical modelling has been used to understand HSV2 spread and its interaction with HIV, and summarises findings on antiviral treatment and behaviour change. It lists further modelling needs, such as drug resistance, cost-effectiveness and vaccine effects.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mathematical modelling",
          "heading": true
        },
        {
          "term": "hsv",
          "heading": false
        },
        {
          "term": "seroprevalence",
          "heading": false
        },
        {
          "term": "recurrences",
          "heading": false
        },
        {
          "term": "antiviral",
          "heading": false
        },
        {
          "term": "duration",
          "heading": false
        },
        {
          "term": "validity",
          "heading": false
        },
        {
          "term": "spread",
          "heading": false
        }
      ],
      "extract": "interactions between HSV2 and HIV.The modelling allows improved understanding of the mechanisms of STI spread by analysing, interpreting and identifying gaps in empirical data and guiding future field studies. However, as the validity of the output depends on the validity of the input, modelling does not usually provide quantitative certainty. Modelling HSV2 spread has highlighted that sexual behaviour patterns,",
      "extractCut": true
    },
    {
      "id": "sec-015-8-hsv2-diagnosis",
      "number": "8",
      "title": "HSV2 DIAGNOSIS",
      "level": 1,
      "pageStart": 34,
      "pageEnd": 36,
      "labelStart": "27",
      "labelEnd": "29",
      "words": 473,
      "summary": {
        "text": "Reviews HSV2 diagnostic methods, including gold-standard Western blot, commercial ELISA tests, ways to measure incidence, and PCR detection of viral shedding. It lists research needs, such as evaluating assays on African sera and developing rapid tests for herpetic ulcers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hsv diagnosis",
          "heading": true
        },
        {
          "term": "recurrent hsv",
          "heading": false
        },
        {
          "term": "hsv dna",
          "heading": false
        },
        {
          "term": "commercial assays",
          "heading": false
        },
        {
          "term": "herpes simples",
          "heading": false
        },
        {
          "term": "western blot",
          "heading": false
        },
        {
          "term": "african sera",
          "heading": false
        },
        {
          "term": "quantitative pcr",
          "heading": false
        }
      ],
      "extract": "Evaluation of HSV2 assays is based on sensitivity, specificity and reproducibility, and independent blinded comparison. SEROLOGY AND DIRECT TECHNIQUES TO DETECT HSV2 INFECTION The gold standards for HSV2 serology include Western blot and immunoblot enzyme assays.These assays are based on detecting type-specific epitopes present within glycoproteins G and C (gG and gC).Western Blot is time consuming, expensive and",
      "extractCut": true
    },
    {
      "id": "sec-016-9-research-and-control-programme-priorities",
      "number": "9",
      "title": "RESEARCH AND CONTROL PROGRAMME PRIORITIES",
      "level": 1,
      "pageStart": 36,
      "pageEnd": 37,
      "labelStart": "29",
      "labelEnd": "30",
      "words": 320,
      "summary": {
        "text": "Introduces the agreed research and control priorities, starting with epidemiology and natural history, such as testing stored and sentinel surveillance sera for HSV2 prevalence and using cohort data to study the effect of HSV2 on HIV acquisition by sex and age.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hsv prevalence",
          "heading": false
        },
        {
          "term": "hsv transmission",
          "heading": false
        },
        {
          "term": "obtain hsv",
          "heading": false
        },
        {
          "term": "hsv infection",
          "heading": false
        },
        {
          "term": "natural history",
          "heading": false
        },
        {
          "term": "surveillance sera",
          "heading": false
        },
        {
          "term": "priorities",
          "heading": true
        },
        {
          "term": "prevalence data",
          "heading": false
        }
      ],
      "extract": "Agreed priorities for control programmes and future research are summarized below. 9.1. EPIDEMIOLOGICAL STUDIES AND NATURAL HISTORY OF HSV2 ■Analysis of sera from past and present studies to obtain HSV2 prevalence data Limited data on HSV2 prevalence are available at present. It was recommended that stored sera from past and current studies be tested in order to increase data on HSV2 prevalence and incidence in",
      "extractCut": true
    },
    {
      "id": "sec-017-92-biological-studies-hsv2-and-its-interaction-w",
      "number": "9.2",
      "title": "Biological studies: HSV2 and its interaction with HIV",
      "level": 2,
      "pageStart": 37,
      "pageEnd": 37,
      "labelStart": "30",
      "labelEnd": "30",
      "words": 127,
      "summary": {
        "text": "Sets out the priority for clinical studies of how subclinical HSV2 shedding affects HIV shedding and transmission, ideally in areas with high rates of both infections.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hsv",
          "heading": true
        },
        {
          "term": "hsv shedding",
          "heading": false
        },
        {
          "term": "hiv shedding",
          "heading": false
        },
        {
          "term": "hsv infection",
          "heading": false
        }
      ],
      "extract": "■Clinical studies to assess the effect of subclinical HSV2 infection on HIV shedding There is strong evidence of the bi-directional interaction between HIV and HSV2 in co- infected subjects. However, there is insufficient evidence concerning the effect of asymptomatic HSV2 shedding on HIV transmission. Studies of HIV shedding in HSV2- infected subjects, and of the relative importance of unrecognized HSV2 infection",
      "extractCut": true
    },
    {
      "id": "sec-018-93-episodic-and-suppressive-therapy",
      "number": "9.3",
      "title": "Episodic and suppressive therapy",
      "level": 2,
      "pageStart": 37,
      "pageEnd": 39,
      "labelStart": "30",
      "labelEnd": "32",
      "words": 549,
      "summary": {
        "text": "Lists treatment-related priorities, including monitoring the causes of genital ulcers in clinic attenders by sex and HIV status, assessing aciclovir in syndromic management, and studying the effect of episodic therapy on HIV shedding. It also calls for randomised trials of suppressive therapy to prevent HIV in high-risk groups.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "episodic therapy",
          "heading": true
        },
        {
          "term": "suppressive therapy",
          "heading": true
        },
        {
          "term": "gud aetiology",
          "heading": false
        },
        {
          "term": "episodic herpes",
          "heading": false
        },
        {
          "term": "aciclovir",
          "heading": false
        },
        {
          "term": "herpes simples",
          "heading": false
        },
        {
          "term": "hiv shedding",
          "heading": false
        },
        {
          "term": "syndromic management",
          "heading": false
        }
      ],
      "extract": "■Monitoring GUD aetiology in STI clinic attenders by gender and HIV status Changes in the aetiology of GUD in some countries has been associated with an increase in the frequency of treatment failure when using the syndromic approach to diagnose and treat STIs. High priority should be given to studies of GUD aetiology, especially in areas in which the proportion of ulcers of unknown aetiology is large and where HIV",
      "extractCut": true
    },
    {
      "id": "sec-019-94-vaccination",
      "number": "9.4",
      "title": "Vaccination",
      "level": 2,
      "pageStart": 39,
      "pageEnd": 40,
      "labelStart": "32",
      "labelEnd": "33",
      "words": 126,
      "summary": {
        "text": "Proposes a working group to engage vaccine companies, lobby for prophylactic vaccine development and affordability in developing countries, and advance the DISC vaccine to later-phase trials.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "disc vaccine",
          "heading": false
        },
        {
          "term": "hsv vaccine",
          "heading": false
        },
        {
          "term": "vaccine development",
          "heading": false
        },
        {
          "term": "vaccine products",
          "heading": false
        },
        {
          "term": "lobby",
          "heading": false
        }
      ],
      "extract": "It was agreed to form a working group to establish a dialogue with commercial companies involved in HSV2 vaccine development and production.The group should engage these companies in discussions regarding further development and testing of the two types of HSV2 vaccine, prophylactic and therapeutic. Specifically, the group would: ■Lobby for further investment in prophylactic vaccine development, including",
      "extractCut": true
    },
    {
      "id": "sec-020-95-behavioural-and-microbicide-studies",
      "number": "9.5",
      "title": "Behavioural and microbicide studies",
      "level": 2,
      "pageStart": 40,
      "pageEnd": 40,
      "labelStart": "33",
      "labelEnd": "33",
      "words": 158,
      "summary": {
        "text": "Lists behavioural and microbicide priorities, including continued promotion of behaviour change and condoms, evaluation of HSV2 counselling and clinic management of herpes, and including HSV2 as an outcome in microbicide trials.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hsv infection",
          "heading": false
        },
        {
          "term": "counselling strategies",
          "heading": false
        },
        {
          "term": "microbicide",
          "heading": true
        },
        {
          "term": "young people",
          "heading": false
        },
        {
          "term": "behavioural",
          "heading": true
        },
        {
          "term": "condom",
          "heading": false
        }
      ],
      "extract": "■Re-emphasis on primary prevention: behaviour modification and condom use Continued emphasis must be placed on reducing exposure to HSV2 and HIV through behavioural modiﬁcation and condom use.These messages are particularly important for young people, who are at very high risk of HSV2 infection in many developing countries. ■Evaluate counselling strategies for HSV2 in seropositive individuals Evaluation of HSV2",
      "extractCut": true
    },
    {
      "id": "sec-021-96-mathematical-modelling",
      "number": "9.6",
      "title": "Mathematical modelling",
      "level": 2,
      "pageStart": 40,
      "pageEnd": 41,
      "labelStart": "33",
      "labelEnd": "34",
      "words": 82,
      "summary": {
        "text": "Recommends further modelling of HSV2 transmission and control, drug resistance, the cost-effectiveness of treatment strategies and the effects of vaccination on HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "modelling",
          "heading": true
        },
        {
          "term": "hsv",
          "heading": false
        },
        {
          "term": "mathematical",
          "heading": true
        }
      ],
      "extract": "Work should continue on mathematical modelling allowing prediction of the impact of alternative control approaches on the HIV and HSV2 epidemics in a given population. ■Continue modelling the transmission and control of HSV2, and its interaction with HIV ■Model the risk of development of drug resistance ■Model cost-effectiveness of alternative treatment strategies ■Model the effects of vaccination, including",
      "extractCut": true
    },
    {
      "id": "sec-022-97-diagnosis",
      "number": "9.7",
      "title": "Diagnosis",
      "level": 2,
      "pageStart": 41,
      "pageEnd": 42,
      "labelStart": "34",
      "labelEnd": "35",
      "words": 115,
      "summary": {
        "text": "Lists diagnostic priorities: rapid tests for herpes ulcers to guide syndromic management, and evaluation of serological tests on African sera.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "herpes simples",
          "heading": false
        },
        {
          "term": "simples virus",
          "heading": false
        },
        {
          "term": "research priorities",
          "heading": false
        },
        {
          "term": "current serological",
          "heading": false
        }
      ],
      "extract": "■Rapid diagnostic tests for herpes ulcers Evaluation of algorithms for syndromic management of GUD is needed, with possible use of aciclovir for severe ulcers.To avoid over-treatment, development of rapid diagnostic assays for GUD should be a high priority. ■Evaluation of current serological tests on panels of African sera Studies of the performance of current serological assays are needed to investigate discrepant",
      "extractCut": true
    },
    {
      "id": "sec-023-annex-1-list-of-participants",
      "number": "Annex 1",
      "title": "LIST OF PARTICIPANTS",
      "level": 1,
      "pageStart": 42,
      "pageEnd": 45,
      "labelStart": "35",
      "labelEnd": "38",
      "words": 1421,
      "summary": {
        "text": "Annex 1, the list of workshop participants with their institutions and contact details, running into the start of the reference list.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "keppel street",
          "heading": false
        },
        {
          "term": "london wc1e",
          "heading": false
        },
        {
          "term": "herpes simplex",
          "heading": false
        },
        {
          "term": "tropical medicine",
          "heading": false
        },
        {
          "term": "london school",
          "heading": false
        },
        {
          "term": "tel",
          "heading": false
        },
        {
          "term": "tropical diseases",
          "heading": false
        },
        {
          "term": "genital herpes",
          "heading": false
        }
      ],
      "extract": "Michel Alary Department of Infectious and Tropical Diseases London School of Hygiene and Tropical Medicine Keppel Street London WC1E 7HT United Kingdom Tel: +44 20 7612 7972 Fax: +44 20 7637 4314 Email: michel.alary@lshtm.ac.uk Sevgi Aral Division of STD Prevention/CDC 1600 Clifton Road Mail-stop E02 Atlanta, GA 30333 USA Tel: +1 404 639 8259 Fax: +1 404639 8608 Email: soa1@cdc.gov Mamadou Ball World Health",
      "extractCut": true
    },
    {
      "id": "sec-024-annex-2-references",
      "number": "Annex 2",
      "title": "REFERENCES",
      "level": 1,
      "pageStart": 45,
      "pageEnd": 52,
      "labelStart": "38",
      "labelEnd": null,
      "words": 1845,
      "summary": {
        "text": "The reference list for the report, citing mainly studies on HSV2 epidemiology, treatment, vaccines and interaction with HIV, ending with WHO and UNAIDS contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "herpes simplex",
          "heading": false
        },
        {
          "term": "genital herpes",
          "heading": false
        },
        {
          "term": "simplex virus",
          "heading": false
        },
        {
          "term": "herpes simples",
          "heading": false
        },
        {
          "term": "genital hsv",
          "heading": false
        },
        {
          "term": "asymptomatic herpes",
          "heading": false
        },
        {
          "term": "herpes infections",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        }
      ],
      "extract": "38 ANNEX 2. REFERENCES HERPES SIMPLES VIRUS TYPE 2: PROGRAMMATIC AND RESEARCH PRIORITIES IN DEVELOPING COUNTRIES Corey L, Mindel A, Fife KH, Sutherland S, Benedetti J,Adler MW. Risk of recurrence after treatment of ﬁrst-episode genital herpes with intravenous aciclovir. Sex Trans Dis 1985; 12 (4):215-218. Corey L, Langenberg AGM,Ashley R, Sekulovich RE, Izu AE, Douglas JM, Handsfield HH et al. Recombinant",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 4,
        "items": [
          "4.1 EPIDEMIOLOGY OF HSV2",
          "4 EPIDEMIOLOGY AND NATURAL HISTORY OF HSV2",
          "4.2 NATURAL HISTORY OF HSV2",
          "9.1 EPIDEMIOLOGICAL STUDIES AND NATURAL HISTORY OF HSV2"
        ]
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "genital hsv",
      "heading": false
    },
    {
      "term": "hsv shedding",
      "heading": false
    },
    {
      "term": "hsv infection",
      "heading": false
    },
    {
      "term": "hsv transmission",
      "heading": false
    },
    {
      "term": "hsv prevalence",
      "heading": true
    },
    {
      "term": "hsv control",
      "heading": true
    },
    {
      "term": "subclinical hsv",
      "heading": false
    },
    {
      "term": "hsv therapy",
      "heading": true
    },
    {
      "term": "hsv acquisition",
      "heading": false
    },
    {
      "term": "hsv vaccine",
      "heading": false
    },
    {
      "term": "hsv disease",
      "heading": false
    },
    {
      "term": "hsv recurrence",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 2,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 3,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 4,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 5,
      "label": "iv",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 6,
      "label": "v",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 7,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 8,
      "label": "1",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 9,
      "label": "2",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 10,
      "label": "3",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 11,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 12,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 13,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 14,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 15,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 16,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 17,
      "label": "10",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 18,
      "label": "11",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 19,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 20,
      "label": "13",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 21,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 22,
      "label": "15",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 23,
      "label": "16",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 24,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 25,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 26,
      "label": "19",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 27,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 28,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 29,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 30,
      "label": "23",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 31,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 32,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 33,
      "label": "26",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 34,
      "label": "27",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 35,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 36,
      "label": "29",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 37,
      "label": "30",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 38,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 39,
      "label": "32",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 40,
      "label": "33",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 41,
      "label": "34",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 42,
      "label": "35",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 43,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 44,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 45,
      "label": "38",
      "source": "contents",
      "confidence": 0.6
    },
    {
      "physical": 46,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 47,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 48,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 49,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 50,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 51,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 52,
      "label": null,
      "source": null,
      "confidence": 0
    }
  ],
  "figures": [
    {
      "kind": "table",
      "number": "1",
      "title": "HSV2 seroprevalence in general populations in developing countries Country",
      "page": 12,
      "pageLabel": null,
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "2",
      "title": "Aetiology of GUD in a gold mine STI clinic, South Africa 1986-98 1986",
      "page": 21,
      "pageLabel": null,
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1: HSV2 seroprevalence in general populations in developing countries",
      "pages": [
        12
      ],
      "columns": [
        {
          "titles": "Country"
        },
        {
          "titles": "Population"
        },
        {
          "titles": "Year"
        },
        {
          "titles": "Prevalence¹"
        },
        {
          "titles": "Reference"
        }
      ],
      "rows": [
        [
          "Uganda",
          "Adults (rural)",
          "1989",
          "74% (f); 57% (m)",
          "Wagner et al, 1994"
        ],
        [
          "Congo",
          "Adults (urban)",
          "1982",
          "71%",
          "Nahmias et al, 1990"
        ],
        [
          "Kenya",
          "Adults (urban)",
          "1997",
          "68% (f); 35% (m)",
          "Weiss et al, 2001"
        ],
        [
          "Zambia",
          "Adults (urban)",
          "1997",
          "55% (f); 36% (m)",
          "Weiss et al, 2001"
        ],
        [
          "Rwanda",
          "Hospital workers (rural)",
          "1985",
          "51%",
          "Nahmias et al, 1990"
        ],
        [
          "Cameroon",
          "Adults (urban)",
          "1997",
          "51% (f); 27% (m)",
          "Weiss et al, 2001"
        ],
        [
          "Costa Rica",
          "Adult women",
          "1985",
          "43% (f)",
          "Nahmias et al, 1990"
        ],
        [
          "Tanzania",
          "Adults (rural)",
          "1993",
          "42%(f);19%(m)²",
          "Obasi et al, 1999"
        ],
        [
          "Brazil",
          "Adults (urban)",
          "1990/91",
          "42%",
          "Smith et al, 2001"
        ],
        [
          "Zaire",
          "Adults (urban)",
          "1985",
          "41%",
          "Nahmias et al, 1990"
        ],
        [
          "Rwanda",
          "Adults (rural)",
          "1985",
          "33%",
          "Nahmias et al, 1990"
        ],
        [
          "Benin",
          "Adults (urban)",
          "1997",
          "30% (f); 12% (m)",
          "Weiss et al, 2001"
        ],
        [
          "Brazil",
          "Blood donors (urban)",
          "1994",
          "29%",
          "Da Rosa-Santos et al, 1996"
        ],
        [
          "Rwanda",
          "Army Recruits (rural)",
          "1985",
          "28% (m)",
          "Nahmias et al, 1990"
        ],
        [
          "Senegal",
          "Surgical patients (urban)",
          "1985",
          "20%",
          "Nahmias et al, 1990"
        ],
        [
          "Philippines",
          "Adults (urban)",
          "1991/93",
          "9%",
          "Smith et al, 2001"
        ],
        [
          "China",
          "Gynaecology clinic (urban)",
          "1984-5",
          "2% (f)",
          "Nahmias et al, 1990"
        ]
      ],
      "notes": "¹ (f) females; (m) males ² Age-weighted sample: younger age-groups were over-represented",
      "narratives": {
        "en": "The table lists studies of HSV2 seroprevalence in general populations in developing countries, giving for each the country, population group, year, prevalence (by sex where reported) and reference. Rows are ordered by decreasing prevalence.",
        "ar": "يسرد الجدول دراسات عن معدل الانتشار المصلي لفيروس الهربس البسيط من النمط 2 بين عموم السكان في البلدان النامية، ويبيّن لكل منها البلد، والفئة السكانية، والسنة، ومعدل الانتشار (حسب الجنس حيثما أُبلغ عنه)، والمرجع. والصفوف مرتبة تنازلياً حسب معدل الانتشار.",
        "zh": "本表列出发展中国家一般人群中单纯疱疹病毒2型血清流行率的研究，每项研究给出国家、人群、年份、流行率（如有报告则按性别分列）及参考文献。各行按流行率从高到低排列。",
        "es": "El cuadro enumera estudios de seroprevalencia del VHS-2 en la población general de países en desarrollo e indica para cada uno el país, el grupo de población, el año, la prevalencia (por sexo cuando se notifica) y la referencia. Las filas están ordenadas por prevalencia decreciente.",
        "fr": "Le tableau présente des études de séroprévalence du HSV-2 dans la population générale de pays en développement, en indiquant pour chacune le pays, le groupe de population, l’année, la prévalence (par sexe lorsqu’elle est rapportée) et la référence. Les lignes sont classées par prévalence décroissante.",
        "ru": "В таблице перечислены исследования серопревалентности ВПГ-2 среди населения в целом в развивающихся странах; для каждого указаны страна, группа населения, год, распространенность (по полу, если она сообщалась) и источник. Строки упорядочены по убыванию распространенности."
      },
      "csv": "tables/table-1.csv"
    },
    {
      "label": "Table 2",
      "caption": "Table 2. Aetiology of GUD in a gold mine STI clinic, South Africa 1986-98",
      "pages": [
        21
      ],
      "columns": [
        {
          "titles": ""
        },
        {
          "titles": "1986 [n = 239]"
        },
        {
          "titles": "1990 [n = 213]"
        },
        {
          "titles": "1994 [n = 250]"
        },
        {
          "titles": "1998 [n = 200]"
        }
      ],
      "rows": [
        [
          "Single aetiology",
          "",
          "",
          "",
          ""
        ],
        [
          "Chancroid",
          "127 (53.1)¹",
          "107 (50.2)",
          "94 (37.6)",
          "65 (32.5)"
        ],
        [
          "LGV",
          "8 (3.3)",
          "2 (0.9)",
          "8 (3.2)",
          "9 (4.5)"
        ],
        [
          "Genital herpes",
          "3 (1.3)",
          "3 (1.4)",
          "25 (10.0)",
          "47 (23.5)"
        ],
        [
          "RPR positive",
          "29 (12.1)",
          "17 (8.0)",
          "22 (8.8)",
          "6 (3.0)"
        ],
        [
          "Total",
          "167 (69.8)",
          "129 (60.6)",
          "149 (59.6)",
          "127 (63.5)"
        ],
        [
          "Mixed infection",
          "",
          "",
          "",
          ""
        ],
        [
          "Chancroid + RPR",
          "28 (11.7)",
          "18 (8.5)",
          "13 (5.2)",
          "10 (5.0)"
        ],
        [
          "Chancroid + LGV",
          "6 (2.5)",
          "3 (1.4)",
          "3 (1.2)",
          "1 (0.5)"
        ],
        [
          "Chancroid + LGV + RPR",
          "0",
          "1 (0.5)",
          "1 (0.4)",
          "0"
        ],
        [
          "LGV + RPR",
          "2 (0.8)",
          "0",
          "2 (0.8)",
          "2 (1.0)"
        ],
        [
          "G. herpes + LGV + RPR",
          "0",
          "1 (0.5)",
          "0",
          "0"
        ],
        [
          "G. herpes + LGV",
          "0",
          "0",
          "1 (0.4)",
          "0"
        ],
        [
          "G. herpes + RPR",
          "2 (0.8)",
          "0",
          "4 (1.6)",
          "4 (2.0)"
        ],
        [
          "G. herpes + Chancroid + RPR",
          "1 (0.4)",
          "0",
          "2 (0.8)",
          "0"
        ],
        [
          "G. herpes + Chancroid",
          "2 (0.8)",
          "4 (1.9)",
          "4 (1.6)",
          "19 (9.5)"
        ],
        [
          "Total",
          "41 (17.2)",
          "27 (12.7)",
          "30 (12.0)",
          "36 (18.0)"
        ],
        [
          "Indeterminate",
          "31 (13.0)",
          "57 (26.7)",
          "71 (28.4)",
          "37 (18.5)"
        ]
      ],
      "notes": "¹ Percentage distribution shown in parentheses. [Transcriber: the header prints the year and the sample size [n = …] on two rows; they are combined in each column title.]",
      "narratives": {
        "en": "The table shows the aetiology of genital ulcer disease (GUD) among patients at a gold mine STI clinic in South Africa in 1986, 1990, 1994 and 1998, as numbers with percentage distribution. Rows give single aetiologies (chancroid, LGV, genital herpes, RPR positive), mixed infections, their totals and indeterminate cases.",
        "ar": "يبيّن الجدول مسببات مرض القرحة التناسلية بين المرضى في عيادة للعدوى المنقولة جنسياً في منجم ذهب بجنوب أفريقيا في الأعوام 1986 و1990 و1994 و1998، بالأعداد مع التوزيع النسبي المئوي. وتعرض الصفوف المسببات المفردة (القريح، والورم الحبيبي اللمفي التناسلي، والهربس التناسلي، وإيجابية اختبار RPR)، والعداوى المختلطة، ومجاميعها، والحالات غير المحددة.",
        "zh": "本表显示南非一家金矿性传播感染诊所1986、1990、1994和1998年生殖器溃疡病的病因，以例数及百分比分布表示。各行列出单一病因（软下疳、性病淋巴肉芽肿、生殖器疱疹、RPR阳性）、混合感染、各自合计以及病因不明病例。",
        "es": "El cuadro muestra la etiología de la úlcera genital en pacientes de un consultorio de ITS de una mina de oro de Sudáfrica en 1986, 1990, 1994 y 1998, en números y distribución porcentual. Las filas recogen las etiologías únicas (chancroide, LGV, herpes genital, RPR positivo), las infecciones mixtas, sus totales y los casos indeterminados.",
        "fr": "Le tableau présente l’étiologie des ulcérations génitales chez les patients d’un dispensaire IST d’une mine d’or en Afrique du Sud en 1986, 1990, 1994 et 1998, en effectifs et en répartition en pourcentage. Les lignes indiquent les étiologies uniques (chancre mou, LGV, herpès génital, RPR positif), les infections mixtes, leurs totaux et les cas indéterminés.",
        "ru": "В таблице показана этиология генитальных язв у пациентов клиники ИППП на золотом руднике в Южной Африке в 1986, 1990, 1994 и 1998 гг. в абсолютных числах и процентном распределении. В строках приведены моноэтиологические случаи (мягкий шанкр, венерическая лимфогранулема, генитальный герпес, положительная реакция RPR), смешанные инфекции, их итоги и случаи неустановленной этиологии."
      },
      "csv": "tables/table-2.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 25,
      "note": "inferred"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 26,
      "note": "2 levels"
    },
    {
      "kind": "figures",
      "state": "none"
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 2
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p45); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p5); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 25,
      "note": "25 of 26 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-42458"
  }
}
